Female/male | 21/9 | 16/3 | 8/7 | 7/2 | 13/7 | 4/2 | 4/5 |
Age (range; years) | 9.9 (3.0–15.1) | 9.2 (2.1–17.0) | 10.7 (3.6–17.5) | 10.1 (3.8–17.3) | 9.5 (2.3–14.8) | 10.6 (7.7–13.4) | 10.4 (4.7–13.9) |
Disease duration (range; years) | 5.9 (0.4–14.0) | 4.7 (0.4–14.0 | 2.7 (0.3–7.0) | 4.4 (0.8–8.5) | 4.7 (0.2–11.0) | 5.9 (12.1–10.0) | 6.8 (1.2–12.1) |
Active/non-active disease | 20/10 | 19 | 8/7 | 9 | 13/7 | 6 | |
ESR (mm/h) | 13.2 (2–55) | 31.2 (7–104) | 46.7 (5–171) | 43.0 (7–80) | 13.9 (5–47) | 63.1 (7–171) | ND |
CRP (range; mg/l) | 22.9 (<1–90) | 34.1 (3–90) | 45.0 (2–111) | 35.2 (15–95) | 29.5 (3–110) | 33.0 (18–70) | ND |
ANA positive* | 7 (23%) | 13 (68%) | 2 (13%) | 2 (22%) | 8 (40%) | 0 (0%) | ND |
RF positive† | 0 (0%) | 0 (0%) | 0 (0%) | 1 (11%) | 3 (15%) | 0 (0%) | ND |
NSAID | 24 (80%) | 18 (95%) | 14 (93%) | 8 (89%) | 19 (95%) | 6 (100%) | 0 (0%) |
MTX | 12 (40%) | 8 (42%) | 8 (53%) | 7 (78%) | 11 (55%) | 5 (83%) | 0 (0%) |
Corticosteroids | 1 (3%) | 1 (5%) | 4 (27%) | 2 (22%) | 2 (10%) | 4 (67%) | 0 (0%) |
Anti-TNFα | 0 (0%) | 0 (0%) | 2 (13%) | 1 (11%) | 3 (15%) | 2 (33%) | 0 (0%) |